Compositions and methods for modified b cells expressing reassigned biological agents
AssigneeKota Biotherapeutics, LLC
InventorsRoderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight
Life of this patent
Estimating the term…
Abstract
Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.
Claims23
A modified B cell of expressing:
- at least one exogenously incorporated membrane immunoglobulin or a recombinant receptor that at least does one of binding to a first antigen and is stimulated by a first antigen;
- at least one exogenously incorporated reassigned biological agent, and
- at least one endogenous secreted immunoglobulin reactive to a second antigen.
A modified B cell that is modified for expressing:
- at least one exogenously incorporated membrane immunoglobulin or recombinant receptor that that one of least binds to a first antigen and is stimulated by a first antigen;
- at least one exogenously incorporated reassigned biological agent;
- and
- at least one exogenously incorporated nucleic acid encoding secreted immunoglobulin that at least does one of binding to a second antigen and is stimulated by a second antigen.
A modified B cell capable of for expressing at least one exogenously incorporated membrane immunoglobulin or a recombinant receptor that is reactive to a first antigen;
- and at least one endogenous secreted immunoglobulin reactive to a second antigen;
- at least one exogenously incorporated reassigned biological agent;
- and at least one exogenously incorporated membrane receptor configured to directly or indirectly induce expression of at least one cytotoxic effector molecule.
An modified B cell for expressing at least one exogenously incorporated membrane immunoglobulin or a recombinant receptor that is reactive to a first antigen;
- and at least one exogenous secreted immunoglobulin reactive to a second antigen;
- at least one exogenously incorporated reassigned biological agent;
- and at least one exogenously incorporated membrane receptor configured to directly or indirectly induce expression of at least one cytotoxic effector molecule.
Dependencies are inferred from the claim text.